TABLE 1.
Six chordoma cell lines; established from 3 from clival tumor patients (UM-Chor1, MUG-CC1, UM-Chor5), and 3 sacral tumor patients (JHC7, U-CH1, U-CH2) were analyzed by flow cytometry to quantify expression surface markers MHC-I/HLA-A,B,C, PD-L1, and EGFR. Cell surface expression of each marker is reported in % positive cells and MFI.
| HLA-A,B,C/MHC-I | PD-L1 | EGFR | |||||
|---|---|---|---|---|---|---|---|
| Cell Line | Derivation | % positive | MFI | % positive | MFI | % positive | MFI |
| UM-Chor1 | 66-year-old male Primary clival chordoma |
100 | 7444 | 7.2 | 552 | 86.9 | 879 |
| MUG-CC1 | 72-year-old male Primary clival chordoma |
90.8 | 1781 | 7.4 | 1723 | 24.5 | 2859 |
| UM-Chor5 | <20-year-old male Primary clival chordoma |
97.6 | 4439 | 10.2 | 1167 | 46.0 | 1427 |
| JHC7 | 61-year-old female Primary sacral chordoma |
91.0 | 2042 | 10.9 | 558 | 52.1 | 1094 |
| U-CH1 | 56-year-old male Recurrent sacral chordoma |
92.6 | 4782 | 7.1 | 1600 | 26.4 | 2619 |
| U-CH2 | 72-year-old female Recurrent sacral chordoma |
90.9 | 4301 | 7.5 | 1487 | 40.7 | 2164 |